Polatuzumab vedotin.

Zhu Chenchen (alias), 20, who suffered from diffuse large B-cell lymphoma (DLBCL), has regained confidence in life after seeking medical help in Hainan Boao Lecheng International Medical Tourism Pilot Zone, local media outlets reported on May 28.

DLBCL is the most common type of non-Hodgkin lymphoma (NHL) and is a cancer that starts in lymphocytes. Nearly 40 percent of patients who haven't received any treatment before may relapse after standard treatments, and may face problems of limited follow-up treatments and poor prognosis.

Zhu was diagnosed with DLBCL in March 2019. He came to the Hainan Boao Evergrande International Hospital in November 2020.

An expert group was set up to consider Zhu's condition, as the lymphoma was still spreading after six stages of treatment including R-IGEV, partial radiotherapy and autologous stem cell transplantation. 

After examinations in November 2020, Zhu started to use Polatuzumab vedotin (Pola) to treat his DLBCL, together with rituximab and bendamustine. His condition was partially relieved after two courses of medication. 

The remission rate of Pola in treating DLBCL patients has now exceeded 50 percent based on clinical research. But Pola hasn't received approval to enter the Chinese market.